Novel therapies, including sodium-glucose cotransporter-2 (SGLT2) inhibitors, glucagon-like peptide-1 (GLP-1) agonists, and mineralocorticoid receptor antagonists (MRAs) shown to be effective in conditions such as type 2 diabetes (T2DM), heart failure, and CKD, and it is likely these drugs target shared pathways implicated in metabolic, cardiovascular, and renal disease. The gene discussed is NR3C2; the disease is chronic kidney disease.